An open-label multicenter study of Sipuleucel-T in metastatic castrate resistant prostate cancer patients previously treated with Sipuleucel-T on Dendreon Study P-11
ID Number 11-0812Principal Investigator(s)
Simon J. Hall
Department(s) or Division(s)
The purpose of this study is to learn how your body’s immune system responds after having sipuleucel-T during the first study when you received Sipuleucel-T and having up to three more infusions now after your disease has progressed. Another purpose is to learn about the safety and effectiveness of having up to 3 more infusions of sipuleucel-T. Presently only 3 infusions with sipuleucel-T has been the recommended dose. This study seeks to find out if an additional dose of Sipuleucel-T impacts the immune response and can be given safely.
You may qualify to take part in this research study because you have received sipuleucel-T previously and now your disease is no longer responding to hormone therapy and has spread to other parts of your body.
Recruiting Patients: Yes